Serum biochemical markers for post-concussion syndrome in patients with mild traumatic brain injury.

Abstract

Mild traumatic brain injury (MTBI) is a major public health problem in the United States. A significant subset of MTBI patients develop persistent and distressing neurological, cognitive, and behavioral symptoms, known as the post-concussion syndrome (PCS). To date, multiple studies have assessed the relationship between brain-related proteins found in the serum at the time of injury, and the development of PCS. We conducted a systematic review of prospective cohort studies that assessed the ability of serum biochemical markers to predict PCS after MTBI. A total of 11 studies assessing three different potential biochemical markers of PCS--S100 proteins, neuron-specific enolase (NSE), and cleaved Tau protein (CTP)--met selection criteria. Of these markers, S100 appeared to be the best researched. We conclude that no biomarker has consistently demonstrated the ability to predict PCS after MTBI. A combination of clinical factors in conjunction with biochemical markers may be necessary to develop a comprehensive decision rule that more accurately predicts PCS after MTBI.

• Authors: Tomer Begaz, Demetrios N Kyriacou, Jordana Segal, Jeffrey J Bazarian
• Journal: Journal of neurotrauma (J Neurotrauma) Vol. 23 Issue 8 Pg. 1201-10 (Aug 2006) ISSN: 0897-7151 [Print] United States
• PMID: 16928178 (Publication Type: Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Review, Systematic Review)

Chemical References

• Biomarkers
• S100 Proteins
• tau Proteins
• Phosphopyruvate Hydratase

Topics

• Animals
• Biomarkers (analysis)
• Brain Injuries (diagnosis, metabolism)
• Humans
• Phosphopyruvate Hydratase (analysis, metabolism)
• Post-Concussion Syndrome (metabolism)
• S100 Proteins (analysis, metabolism)
• tau Proteins (analysis, metabolism)